New Data Confirms Efficacy in Masses 2cm or Smaller

New Data Confirms Efficacy in Masses 2cm or Smaller
MELBOURNE, Australia, April 30, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). (PRNewsfoto/Telix Pharmaceuticals Limited) The results were featured in a late-breaking oral presentation delivered on […]










See full article New Data Confirms Efficacy in Masses 2cm or Smaller by Pet News 2Day


#PetFinancialNews

Comments

Popular posts from this blog

Guide Dogs seeking 'puppy raisers' in Bishop's Stortford to change the lives of blind or partially sighted people

Child Bit and Dragged by Dog, Police Searching for Owner

Enter Simply Cats' Valentine's raffle to support kittens while winning prizes